Top Heal Care Stocks To Invest In 2014

 

 NetScout Systems, Inc.  (NASDAQ: NTCT)

Price per share units of NTCT lauched 15.28% (+$3.90) to $29.43 today during mid-day trading session with three hundred plus thousand shares in play Thursday11:47AM EDT October 17, 2013. About four and a half hours prior ticker NTCT, an industry leader for advanced application and service assurance solutions reported firm Q2 notably growth in product revenue. The Company’s product revenue for Q2, on a GAAP and non-GAAP basis was $52.4 million. This increase is believed to be contributed by intentive consumer interest of their new released products in particular nGeniusONE™ platform. nGeniusONE Unified Performance Management Platform enables efficient IT service management with an all-inclusive set of capabilities delivering comprehensive, real-time situational awareness, historical visibility, and contextual, multi-layered performance analysis.

Best Managed Healthcare Stocks To Invest In 2015: Cree Inc.(CREE)

Cree, Inc. develops and manufactures light emitting diodes (LEDs), LED lighting, and semiconductor solutions for wireless and power applications. Its LED products include blue and green LED chips that are used in various applications, including video screens, gaming displays, function indicator lights, and automotive backlighting; LED components comprising a range of packaged LED products and LED modules for lighting applications; LED lighting products, such as LED downlights, LED troffers, and LED lamps or bulbs for construction, retrofit, and renovation projects in commercial, governmental, and residential applications; and silicon carbide (SiC) wafers, which are used in the manufacture of optoelectronics, microwave, power switching, and other applications. The company also provides semiconductor materials and devices primarily based on silicon carbide (SiC), gallium nitride (GaN), and related compounds. Its power and radio frequency (RF) products include SiC-based power products comprising 600, 1,200, and 1,700-volt Schottky diodes, as well as 1,200-volt SiC metal semiconductor field-effect transistor switches that are used in power factor correction circuits for power supplies in computer servers and other applications, such as solar inverters; and RF devices, including a range of GaN high electron mobility transistors and monolithic microwave integrated circuits for military or commercial applications, as well as 10 watt and 60 watt SiC transistors and metal semiconductor field effect transistor products. The company primarily operates in China, the United States, Europe, South Korea, Japan, Malaysia, and Taiwan. Cree, Inc. was formerly known as Cree Research, Inc. and changed its name in January 2000. Cree, Inc. was founded in 1987 and is based in Durham, North Carolina.

Advisors' Opinion:

• [By Eric Volkman]

  Cree (NASDAQ: CREE  ) just-released results revealed a strong Q3 for the LED lighting specialist. For the quarter, net revenue totaled just under $349 million, a substantial gain from the $285 million posted in the same period the previous year. Non-GAAP net profit advanced 75% on a year-over-year basis, coming in at $40.8 million ($0.34 per diluted share) from Q3 2012's $23.3 million ($0.20).

• [By Jake L'Ecuyer]

  Cree (NASDAQ: CREE) was down, falling 10.08 percent to $52.20 on Q3 results. Cree reported its Q3 earnings of $0.39 per share on revenue of $405.30 million. However, analysts were expecting earnings of $0.38 per share on revenue of $407.29 million.

• [By Mani]

  [Related -Cree, Inc. (CREE): Can The LED Maker's Results Show Some Light?]

  Quarterly revenues are expected at $412.36 million, according to analysts polled by Thomson Reuters. The consensus estimate implies growth of 19.1 percent from $346.29 million revenue generated in the year-ago period. Cree targets revenue in a range of $400 million to $420 million.

• [By Lauren Pollock]

  Cree Inc.(CREE) said its fiscal second-quarter earnings rose 75% on broad sales growth for the maker of LED lighting products and semiconductor components. Shares edged up 2.5% to $64.39 premarket.

Top Heal Care Stocks To Invest In 2014: Takeda Pharmaceutical Co Ltd (TKPHF.PK)

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. Advisors' Opinion:

• [By Markus Aarnio]

  Companies working on chemically synthesized siRNAs include Merck (MRK), through its subsidiary Sirna Therapeutics, Inc., Novartis (NVS), Takeda (TKPHF.PK), Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando, Quark, Silence Therapeutics plc, Tekmira (TKMR), Sylentis and Dicerna Pharmaceuticals, Inc.

• [By Alpha Exposure]

  The most recent Affymax article states that Takeda withdrew from consideration for European approval "because they were doing the "root cause analysis" they would not be able to complete the investigation because it was still in process and "ongoing" despite the fact that severe reactions were not present at the time of the clinical trials." However, there is no evidence to support this conclusion. The truth is that we showed you an excerpt directly from the Committee for Medicinal Products for Human Use that stated the CHMP "was of the provisional opinion that Omontys could not have been approved" due to "study results indicating that Omontys may increase the risk of death or heart and circulatory problems." It is clear that the EU application was withdrawn because Takeda (TKPHF.PK) could not get Omontys approved due to its safety profile.

Top Heal Care Stocks To Invest In 2014: Stereotaxis Inc.(STXS)

Stereotaxis, Inc. designs, manufactures, and markets cardiology instrument control systems for use in a hospital?s interventional surgical suite or interventional lab for the treatment of arrhythmias and coronary artery diseases in the United States and internationally. The company provides Niobe system, which includes Niobe Magnetic Navigation System that navigates catheters, guidewires, and other delivery devices through complex paths in the blood vessels and chambers of the heart to carry out treatment; Navigant, a user interface or physician control center, which physicians use to visualize and track procedures and to provide instrument control commands that govern the motion of the working tip of the catheter, guidewire, or other interventional device; Cardiodrive, a catheter advancement system to remotely advance and retract the catheter in the patient?s heart. It also offers Odyssey enterprise solutions, which provides information solutions to manage, control, rec ord, and share procedures across networks; acquires remote view of the lab capturing synchronized procedure data for review of important events during cases; and review recorded cases and create snapshots following procedures for clinical reporting, auditing, and presentation. In addition, the company provides disposable interventional devices comprising automated catheters, coronary guidewires, and navigation and ablation systems. It markets its products through its direct sales force, distributors, and sales agents. The company was founded in 1990 and is headquartered in St. Louis, Missouri.

Advisors' Opinion:

• [By Roberto Pedone]

  One under-$10 health care player that looks poised for a potentially large move higher is Stereotaxis (STXS), which designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. This stock has been on fire so far in 2013, with shares up big by 43%.

  If you take a look at the chart for Stereotaxis, you'll notice that this stock has formed a major bottom pattern over the last three months, since this stock has found buying interest each time it has pulled back towards $3.50 and $3.10 a share. Buyers have stepped in at those levels and have not let the sellers pressure STXS lower. Shares of STXS are now starting to spike higher today right off its 50-day moving average of $3.59 a share. That spike is quickly pushing shares of STXS within range of triggering a big breakout trade above a key downtrend line.

  Traders should now look for long-biased trades in STXS if it manages to break out above some near-term overhead resistance at $4 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.98 million shares. If that breakout triggers soon, then STXS will set up to re-test or possibly take out its next major overhead resistance levels at $5 to $6.24 a share. Any high-volume move above $6.24 a share will then give STXS a chance to re-fill some of its previous gap down zone from August that started at $10 a share.

  Traders can look to buy STXS off any weakness to anticipate that breakout and simply use a stop that sits right below those key support levels at $3.50 to $3.10 a share. One can also buy STXS off strength once it clears $4 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Bryan Murphy]

  Look out Intuitive Surgical, Inc. (NASDAQ:ISRG), and step aside BioTelemetry Inc. (NASDAQ:BEAT). There's a new cardiac name in town, and its name is Stereotaxis Inc. (NASDAQ:STXS). This small company's stock is soaring today on the heels of encouraging news, though the prompt for the stock's strength has been brewing for quite some time. This nudge for STXS, however, may well mean it has a lot more potential than ISRG or BEAT do for the foreseeable future.

Top Heal Care Stocks To Invest In 2014: Newcrest Mining Ltd (NCMGF)

Newcrest Mining Limited (Newcrest) is a gold, copper and silver producer that has operations and exploration projects in Australia, the Pacific region, Asia and West Africa. The Company�� segments include Cadia Valley, Telfer, Gosowong, Lihir, Hidden Valley JV, West Africa (includes Bonikro operations and exploration and evaluation activities in Cote d��voire) and Exploration and Other. Exploration and Other mainly consists of projects in the exploration, evaluation and feasibility phase and includes Namosi in Fiji, Wafi Golpu in Papua New Guinea (PNG), and Marsden and O��allaghans in Australia. Cadia Valley Operations (CVO) is a gold mining operation and is 100% owned by Newcrest. It is located approximately 25 kilometers from the city of Orange in central west New South Wales and is 250 kilometers west of Sydney. Advisors' Opinion:

• [By WWW.MARKETWATCH.COM]

  LOS ANGELES (MarketWatch) -- A soft lead from Wall Street and uncertainty ahead of Australian retail sales data (and U.S. jobs data) aren't slowing the Sydney market, where the S&P/ASX 200 stock benchmark is up 0.5% early Thursday, mainly on a gains for commodities. With copper at a fourth-month high and Chinese spot iron-ore prices moving further off their recent lows, Australia's heavily weighted mining stocks are trading broadly higher: BHP Billiton Ltd. (AU:BHP) (BHP) is up 0.7%, Rio Tinto Ltd. (AU:RIO) (RIO) is up 0.5%, Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) is up 2.5%, Mount Gibson Iron Ltd. (AU:MGX) is up 3.7%, Oz Minerals Ltd. (AU:OZL) (OZMLF) is up 1.7%, and Newcrest Mining Ltd. (AU:NCM) (NCMGF) is up 1.8%. Casino operator Crown Resorts Ltd. (CWLDF) is up 1.2% as Bell Potter reiterates its buy call on the shares, even as it cuts its target price, according to Dow Jones Newswires. On the downside, David Jones Ltd. (AU:DJS) (DVDJF) is down 0.5% as Australian media reports say the nation's regulators failed to get permission to open an investigation into the retailer's proposed takeover by Woolworths of South Africa.

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Stocks in Australia gave up ground early Tuesday before the country's central bank issued its final interest-rate decision of the year. The S&P/ASX 200 (AU:XJO) shed 0.2% to 5,271.10, with financial stocks mixed ahead a widely expected decision by the Reserve Bank of Australia to leave its benchmark rate at 2.5%. Westpac Banking Corp. shares (AU:WBC) (WEBNF) gave up 0.3% and Commonwealth Bank of Australia (AU:CBA) (CBAUF) shed 0.1%, but National Australia Bank Ltd. (AU:NAB) (NAUBF) tacked on 0.3%. Gold stocks were hit, dropping after gold futures fell by more than 2% overnight on concerns about a pullback in monetary stimulus by the U.S. Federal Reserve. Shares of gold miner Newcrest Mining Ltd. (AU:NCM) (NCMGF) lost 6.4%, Evolution Mining Ltd. (AU:EVN) (CAHPF) fell 6.7%, and Kingsgate Consolidated Ltd. (AU:KCN) (KSKGF) slid 9.7%.